Atea Pharmaceuticals Inc. (AVIR)
AVIR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2021-12-31, https://www.sec.gov/Archives/edgar/data/1593899/000095017023005186/0000950170-23-005186-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2021-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | AVIR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001593899 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | MA |
Financials · 2021
| Line | Value |
|---|---|
| Revenue | $351.4M |
| Net income | $121.2M |
| Operating income | $138.4M |
| Net margin | 34.5% |
| Operating margin | 39.4% |
| Revenue growth | +622.5% |
| Cash | $764.4M |
| Total assets | $772.9M |
| P/E (computed) | 2.7× |
| P/S (computed) | 0.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $97.9M cash; operating cash flow -$35.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 80,304,145 (2026-11-06); 78,126,796 a year earlier; 83,435,513 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $25K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$32.2M | -$28.9M | $97.9M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$32.9M | -$37.1M | $76.5M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2026-03-31 | Not filed | -$45.4M | -$46.4M | $79.3M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | Not filed | -$44.9M | -$28.2M | $95.7M | No debt tags | Needs four quarters | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | Not filed | -$42.0M | -$40.4M | $77.3M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | Not filed | -$37.2M | -$32.9M | $87.7M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2025 2025-03-31 | Not filed | -$34.3M | -$30.6M | $119.4M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2024 2024-12-31 | Not filed | -$33.5M | -$30.4M | $64.7M | No debt tags | Needs four quarters | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2024-11-07 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 318 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.2% |
| 1 month | -13.7% |
| 3 months | -15.2% |
| Year to date | +20.4% |
| 1 year | +40.5% |
| From 52-week high | -30.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RZLT | Rezolute Inc. Common Stock (NV) | $3.58 | -2.05% | $346.3M |
| LRMR | Larimar Therapeutics Inc. | $3.00 | -0.66% | $311.6M |
| ENTA | Enanta Pharmaceuticals Inc. | $10.67 | -2.91% | $310.8M |
| BNTC | Benitec Biopharma Inc. | $8.54 | -5.53% | $308.5M |
| ASPE | Aspen Neuroscience Inc. | $12.23 | -2.86% | $355.6M |
| GALT | Galectin Therapeutics Inc. | $3.02 | -0.98% | $305.2M |
| ALT | Altimmune Inc. | $1.56 | -5.17% | $303.6M |
| SPRY | ARS Pharmaceuticals Inc. | $3.59 | -7.71% | $360.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier